Capital & Planning LLC Has $2.33 Million Position in Abbott Laboratories $ABT

Key Points

• Capital & Planning LLC increased its position in Abbott Laboratories by 135.1% in Q4, adding 10,780 shares to hold 18,758 shares valued at about $2.33 million at period end.
• Abbott reported Q4 EPS of $1.50 (in line) and revenue of $11.46B (below estimates), issued FY2026 guidance of 5.55–5.80 EPS and a $0.63 quarterly dividend (2.5% yield), but faces risks from a $53M jury verdict, rising short interest and mixed analyst price‑target cuts despite a "Moderate Buy" consensus.

Capital & Planning LLC increased its position in Abbott Laboratories (NYSE:ABT - Free Report) by 135.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,758 shares of the healthcare product maker's stock after buying an additional 10,780 shares during the period. Capital & Planning LLC's holdings in Abbott Laboratories were worth $2,330,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in ABT. Harbor Capital Advisors Inc. bought a new stake in Abbott Laboratories during the fourth quarter worth approximately $27,000. Cloud Capital Management LLC bought a new stake in Abbott Laboratories during the third quarter worth approximately $29,000. Guerra Advisors Inc bought a new stake in Abbott Laboratories during the third quarter worth approximately $31,000. Delos Wealth Advisors LLC bought a new stake in Abbott Laboratories during the second quarter worth approximately $32,000. Finally, Bridge Generations Wealth Management LLC bought a new stake in Abbott Laboratories during the third quarter worth approximately $33,000. Institutional investors own 75.18% of the company's stock.

Abbott Laboratories Stock Down 2.5%

Shares of ABT stock opened at $100.17 on Friday. The stock has a market cap of $174.46 billion, a P/E ratio of 26.93, a price-to-earnings-growth ratio of 1.60 and a beta of 0.79. Abbott Laboratories has a one year low of $99.34 and a one year high of $139.06. The stock has a fifty day moving average price of $108.92 and a 200 day moving average price of $119.86. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analysts' expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.Abbott Laboratories's quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the business earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories's dividend payout ratio (DPR) is 67.74%.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: TD Cowen reiterated a Buy on ABT and kept a $137 price target, citing a resilient MedTech and diagnostics mix that supports Abbott's path to 2026 targets. TipRanks: TD Cowen Note
• Positive Sentiment: Citi recently initiated/maintained a Buy on ABT (coverage note reported), providing analyst support that can limit downside from headline risk. Globe & Mail: Citi Buy
• Positive Sentiment: Recent coverage highlighting Abbott as a dividend-king value/attractive yield may draw income-focused buyers who view current weakness as a buying opportunity. MarketBeat: Dividend King
• Neutral Sentiment: Abbott published consumer survey PR on chronic disease prevention (brand/marketing relevance). Useful for positioning but unlikely to move the stock materially in the short term. PR Newswire: Survey
• Neutral Sentiment: Wall Street previews note mixed expectations ahead of upcoming earnings (EPS growth expected but edge cases for a beat are limited), so the report could produce volatility but not a clear directional catalyst yet. Yahoo: Earnings Preview
• Negative Sentiment: A Chicago jury ordered Abbott to pay $53 million in compensatory damages in a preterm infant formula trial — a headline legal loss that raises litigation risk and investor concern about reputational and settlement exposure. Reuters: Jury Verdict
• Negative Sentiment: Short interest rose sharply in March (up ~19.4% vs. mid‑March), bringing total shorted shares to ~23.8M and a ~1.6 days-to-cover — increased bearish positioning can amplify downward moves on negative headlines.
• Negative Sentiment: Evercore trimmed its price target (reported) and broader healthcare stocks were weaker today, adding sector pressure; analyst and macro pressure can compound headline-driven selling. American Banking News: Evercore PT Cut

Insider Transactions at Abbott Laboratories

In related news, VP John A. Jr. Mccoy sold 585 shares of the firm's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the transaction, the vice president directly owned 24,628 shares of the company's stock, valued at $2,846,504.24. This trade represents a 2.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of the company's stock in a transaction on Wednesday, February 4th. The shares were bought at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the purchase, the director directly owned 6,738,817 shares of the company's stock, valued at approximately $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders sold 3,055 shares of company stock valued at $353,097 over the last 90 days. Corporate insiders own 0.46% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on ABT. Barclays upped their target price on Abbott Laboratories from $142.00 to $144.00 and gave the stock an "overweight" rating in a research report on Wednesday. BTIG Research reduced their price objective on Abbott Laboratories from $140.00 to $131.00 and set a "buy" rating for the company in a research report on Tuesday, March 31st. Oppenheimer reduced their price objective on Abbott Laboratories from $140.00 to $132.00 and set an "outperform" rating for the company in a research report on Friday, January 23rd. Argus reduced their price objective on Abbott Laboratories from $150.00 to $140.00 in a research report on Tuesday, January 27th. Finally, Royal Bank Of Canada reduced their price objective on Abbott Laboratories from $147.00 to $135.00 and set an "outperform" rating for the company in a research report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $134.58.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.